GR3036954T3 - Quinazoline derivatives - Google Patents

Quinazoline derivatives

Info

Publication number: GR3036954T3
Authority: GR; Greece
Prior art keywords: halogeno; trifluoromethyl; cyano; nitro; alkoxy
Prior art date: 1995-12-18

Application number

GR20010401823T

Other languages

English (en)

Inventor

Jean-Jacques Marcel Lohmann

Laurent F A Hennequin

Andrew Peter Thomas

Original Assignee

Zeneca Ltd

Zeneca Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-18

Filing date

2001-10-19

Publication date

2002-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26140602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3036954(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-10-19 Application filed by Zeneca Ltd, Zeneca Pharma Sa filed Critical Zeneca Ltd

2002-01-31 Publication of GR3036954T3 publication Critical patent/GR3036954T3/el

Links

125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 3
-1 cyano, amino Chemical group 0.000 abstract 3
125000005843 halogen group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
150000003839 salts Chemical class 0.000 abstract 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
125000004423 acyloxy group Chemical group 0.000 abstract 1
125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
125000006615 aromatic heterocyclic group Chemical class 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical class O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Furan Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

GR20010401823T 1995-12-18 2001-10-19 Quinazoline derivatives GR3036954T3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP95402846		1995-12-18
EP96402190		1996-10-15
PCT/GB1996/003075 WO1997022596A1 (en)	1995-12-18	1996-12-13	Quinazoline derivatives
EP96941787A EP0873319B1 (en)	1995-12-18	1996-12-13	Quinazoline derivatives

Publications (1)

Publication Number	Publication Date
GR3036954T3 true GR3036954T3 (en)	2002-01-31

Family

ID=26140602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GR20010401823T GR3036954T3 (en)	1995-12-18	2001-10-19	Quinazoline derivatives

Country Status (29)

Country	Link
US (4)	US5962458A (el)
EP (1)	EP0873319B1 (el)
JP (1)	JP4291413B2 (el)
KR (1)	KR100530311B1 (el)
CN (1)	CN1133625C (el)
AT (1)	ATE203524T1 (el)
AU (1)	AU712370B2 (el)
BR (1)	BR9612043A (el)
CA (1)	CA2237005C (el)
CZ (1)	CZ291100B6 (el)
DE (1)	DE69614147T2 (el)
DK (1)	DK0873319T3 (el)
ES (1)	ES2162656T3 (el)
GB (1)	GB9624482D0 (el)
GR (1)	GR3036954T3 (el)
HU (1)	HUP9901243A3 (el)
IL (1)	IL124925A0 (el)
MX (1)	MX9804247A (el)
MY (1)	MY132405A (el)
NO (1)	NO311358B1 (el)
NZ (1)	NZ324007A (el)
PL (1)	PL192309B1 (el)
PT (1)	PT873319E (el)
RU (1)	RU2194701C2 (el)
SI (1)	SI0873319T1 (el)
SK (1)	SK282443B6 (el)
TR (1)	TR199801115T2 (el)
TW (1)	TW411274B (el)
WO (1)	WO1997022596A1 (el)

Families Citing this family (594)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6228871B1 (en)	1995-07-10	2001-05-08	Merck & Co., Inc.	Angiogenesis inhibitors
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
CA2242425C (en)	1996-02-13	2006-07-18	Zeneca Limited	Quinazoline derivatives as vegf inhibitors
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
CN100503580C (zh)	1996-04-12	2009-06-24	沃尼尔·朗伯公司	酪氨酸激酶的不可逆抑制剂
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
JP3404749B2 (ja)	1996-06-27	2003-05-12	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｎ―［４―（ヘテロアリールメチル）フェニル］―ヘテロアリールアミン
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
CN1252054C (zh)	1996-09-25	2006-04-19	曾尼卡有限公司	抑制生长因子的作用的喹啉衍生物
JP2009007364A (ja) *	1996-10-15	2009-01-15	Astrazeneca Uk Ltd	キナゾリン誘導体
US6225318B1 (en)	1996-10-17	2001-05-01	Pfizer Inc	4-aminoquinazolone derivatives
ZA986729B (en) *	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
DE69838172T2 (de)	1997-08-22	2008-04-10	Astrazeneca Ab	Oxindolylchinazolinderivate als angiogenesehemmer
US6162804A (en) *	1997-09-26	2000-12-19	Merck & Co., Inc.	Tyrosine kinase inhibitors
US6465484B1 (en)	1997-09-26	2002-10-15	Merck & Co., Inc.	Angiogenesis inhibitors
FR2772763B1 (fr) *	1997-12-24	2004-01-23	Sod Conseils Rech Applic	Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6878716B1 (en)	1998-06-02	2005-04-12	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptor and uses thereof
HUP0103836A3 (en)	1998-06-02	2003-05-28	Osi Pharmaceuticals Inc Uniond	Pyrrolo[2,3d]pyrimidine compositions and their use
US6686366B1 (en)	1998-06-02	2004-02-03	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
US20040067227A1 (en) *	2001-11-02	2004-04-08	Goldstein Allan L.	Inhibition or reversal of skin aging by actin-sequestering peptides
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
EE05345B1 (et) *	1999-02-10	2010-10-15	Astrazeneca Ab	Kinasoliini derivaadid angiogeneesi inhibiitoritena
US7049410B2 (en) *	1999-05-14	2006-05-23	Majumdar Adhip P N	Antibodies to a novel EGF-receptor related protein (ERRP)
AU5003200A (en)	1999-05-14	2000-12-05	United States Of America As Represented By The Department Of Veterans Affairs, The	Isolation and characterization of epidermal growth factor related protein
NZ516633A (en)	1999-06-21	2004-09-24	Boehringer Ingelheim Pharma	Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
HK1046688A1 (zh) *	1999-09-21	2003-01-24	Astrazeneca Ab	喹唑啉化合物和含有喹唑啉化合物的藥物組合物
EE200200119A (et)	1999-09-21	2003-04-15	Astrazeneca Ab	Kinasoliini derivaadid ja nende kasutamine ravimitena
SE9903544D0 (sv)	1999-10-01	1999-10-01	Astra Pharma Prod	Novel compounds
PT1244647E (pt) *	1999-11-05	2006-10-31	Astrazeneca Ab	Derivados de quinazolina como inibidores de vegf
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
AU4903201A (en) *	1999-11-30	2001-07-03	Parker Hughes Institute	Inhibitors of thrombin induced platelet aggregation
US6664252B2 (en)	1999-12-02	2003-12-16	Osi Pharmaceuticals, Inc.	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) *	1999-12-02	2007-01-09	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en)	1999-12-02	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
PL357099A1 (en)	2000-02-07	2004-07-12	Abbott Gmbh & Co.Kg	2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
GB2359551A (en)	2000-02-23	2001-08-29	Astrazeneca Uk Ltd	Pharmaceutically active pyrimidine derivatives
AUPQ592100A0 (en) *	2000-02-29	2000-03-23	Council Of The Queensland Institute Of Medical Research, The	A method of treatment and prophylaxis
AU2001235804A1 (en)	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
US20070021392A1 (en) *	2000-03-31	2007-01-25	Davis Peter D	Divided dose therapies with vascular damaging activity
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
IL151626A0 (en) *	2000-04-07	2003-04-10	Astrazeneca Ab	Quinazoline compounds
RU2276151C2 (ru) *	2000-06-06	2006-05-10	Астразенека Аб	Хиназолиновые производные для лечения опухолей
UA73993C2 (uk) *	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AR028948A1 (es)	2000-06-20	2003-05-28	Astrazeneca Ab	Compuestos novedosos
AU2001278609B2 (en)	2000-08-21	2005-04-14	Astrazeneca Ab	Quinazoline derivatives
US6656946B2 (en)	2000-08-26	2003-12-02	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042058A1 (de) *	2000-08-26	2002-03-07	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP4341949B2 (ja)	2000-09-01	2009-10-14	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	アザ複素環式誘導体およびその治療的使用
BRPI0113757B8 (pt) *	2000-09-11	2017-11-07	Chiron Corp	derivados de quinolinona como inibidores de tirosina quinase
US20030028018A1 (en) *	2000-09-11	2003-02-06	Chiron Coporation	Quinolinone derivatives
SE0003828D0 (sv)	2000-10-20	2000-10-20	Astrazeneca Ab	Novel compounds
DE60144284D1 (de)	2000-11-01	2011-05-05	Millennium Pharm Inc	Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
AU2001229722A1 (en) *	2000-11-29	2002-06-11	Parker Hughes Institute	Inhibitors of thrombin induced platelet aggregation
US6680324B2 (en) *	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en)	2000-12-01	2004-01-06	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US7019012B2 (en) *	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
MXPA03005696A (es)	2000-12-21	2003-10-06	Glaxo Group Ltd	Pirimidinaminas como moduladores de angiogenesis.
NZ527302A (en)	2001-01-05	2006-10-27	Abgenix Inc	Antibodies to insulin-like growth factor I receptor
US20070050857A1 (en) *	2001-02-28	2007-03-01	Hayward Nick K	Method of treatment and prophylaxis
MXPA03008560A (es)	2001-03-22	2004-06-30	Abbot Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
WO2002092578A1 (en) *	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
WO2003000194A2 (en)	2001-06-21	2003-01-03	Pfizer Inc.	Thienopyridine and thienopyrimidine anticancer agents
US7132427B2 (en)	2001-06-21	2006-11-07	Ariad Pharmaceuticals, Inc.	Quinazolines and uses thereof
JP4836368B2 (ja) *	2001-08-30	2011-12-14	広栄化学工業株式会社	メチルヒドロキシアルキルピリジン類の製造方法
GB0126433D0 (en) *	2001-11-03	2002-01-02	Astrazeneca Ab	Compounds
RU2004116911A (ru) *	2001-11-03	2005-11-10	Астразенека Аб (Se)	Производные хиназолина в качестве противоопухолевых средств
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
JP2005529062A (ja) *	2001-11-30	2005-09-29	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	アデノシンａ１及びａ３受容体に特異的な化合物とその使用
EP1466907B1 (en) *	2001-12-19	2011-08-10	Ube Industries, Ltd.	Process for producing quinazolin-4-one and derivative thereof
DE60236458D1 (de) *	2001-12-20	2010-07-01	Osi Pharm Inc	Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
KR20040068317A (ko)	2001-12-20	2004-07-30	오에스아이 파마슈티컬스, 인코포레이티드	피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
EP1477481B1 (en) *	2002-01-28	2009-07-22	Ube Industries, Ltd.	Process for producing quinazolin-4-one derivative
EP2292615A1 (en) *	2002-02-01	2011-03-09	AstraZeneca AB	Quinazoline compounds
MXPA04008403A (es)	2002-03-01	2004-11-26	Pfizer	Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso.
TW200813014A (en) *	2002-03-28	2008-03-16	Astrazeneca Ab	Quinazoline derivatives
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US6936641B2 (en) *	2002-06-25	2005-08-30	Johnson & Johnson Vision Care, Inc.	Macromer forming catalysts
EP1521747B1 (en) *	2002-07-15	2018-09-05	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
GB0217431D0 (en)	2002-07-27	2002-09-04	Astrazeneca Ab	Novel compounds
EP2573079A3 (en) *	2002-08-23	2015-03-11	Novartis AG	Benzimidazole quinolinones and uses thereof
US7825132B2 (en) *	2002-08-23	2010-11-02	Novartis Vaccines And Diagnostics, Inc.	Inhibition of FGFR3 and treatment of multiple myeloma
AU2003257666A1 (en) *	2002-08-23	2004-03-11	Kirin Beer Kabushiki Kaisha	COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
US20050256157A1 (en) *	2002-08-23	2005-11-17	Chiron Corporation	Combination therapy with CHK1 inhibitors
AU2003255819A1 (en)	2002-08-24	2004-03-11	Astrazeneca Ab	Pyrimidine derivatives as modulators of chemokine receptor activity
GB0221828D0 (en)	2002-09-20	2002-10-30	Astrazeneca Ab	Novel compound
RU2350618C2 (ru) *	2002-11-04	2009-03-27	Астразенека Аб	ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
SG148864A1 (en) *	2002-11-13	2009-01-29	Chiron Corp	Methods of treating cancer and related methods
AU2003286321A1 (en)	2002-12-19	2004-07-14	Pfizer Inc.	2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
UA83814C2 (ru)	2002-12-24	2008-08-26	Астразенека Аб	Производные фосфонооксихиназолина и их фармацевтическое применение
US7223749B2 (en) *	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
PT2476667E (pt)	2003-02-26	2014-09-18	Sugen Inc	Compostos de aminoheteroarilo como inibidores da proteína quinase
GB0309009D0 (en) *	2003-04-22	2003-05-28	Astrazeneca Ab	Quinazoline derivatives
GB0309850D0 (en)	2003-04-30	2003-06-04	Astrazeneca Ab	Quinazoline derivatives
SE0301569D0 (sv)	2003-05-27	2003-05-27	Astrazeneca Ab	Novel compounds
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
GB0318423D0 (en) *	2003-08-06	2003-09-10	Astrazeneca Ab	Chemical compounds
NZ592039A (en)	2003-08-27	2013-03-28	Ophthotech Corp	Combination therapy for the treatment of ocular neovascular disorders
WO2005021554A1 (en)	2003-08-29	2005-03-10	Pfizer Inc.	Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
GB0321648D0 (en) *	2003-09-16	2003-10-15	Astrazeneca Ab	Quinazoline derivatives
MXPA06002963A (es) *	2003-09-16	2006-06-14	Astrazeneca Ab	Derivados de quinazolina como inhibidores de cinasa de tirosina.
WO2005026150A1 (en)	2003-09-16	2005-03-24	Astrazeneca Ab	Quinazoline derivatives as tyrosine kinase inhibitors
DE602004004811T2 (de) *	2003-09-19	2007-11-22	Astrazeneca Ab	Chinazolinderivate
BRPI0414532B1 (pt) *	2003-09-19	2018-06-05	Astrazeneca Ab	Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
MXPA06003341A (es) *	2003-09-25	2006-06-08	Astrazeneca Ab	Derivados de quinazolina.
EP2210607B1 (en) *	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
ES2372694T3 (es)	2003-10-15	2012-01-25	OSI Pharmaceuticals, LLC	Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
JP4823914B2 (ja) *	2003-11-07	2011-11-24	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
KR101190912B1 (ko)	2003-11-19	2012-10-12	어레이 바이오파마 인크.	Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
GB0328243D0 (en)	2003-12-05	2004-01-07	Astrazeneca Ab	Methods
AP2006003619A0 (en)	2003-12-23	2006-06-30	Pfizer	Novel quinoline derivatives
GB0330002D0 (en)	2003-12-24	2004-01-28	Astrazeneca Ab	Quinazoline derivatives
JP2007517843A (ja)	2004-01-05	2007-07-05	アストラゼネカアクチボラグ	Ｃｈｋ１阻害剤であるチオフェン誘導体
WO2005070891A2 (en) *	2004-01-23	2005-08-04	Amgen Inc	Compounds and methods of use
EP1718306A2 (en) *	2004-02-20	2006-11-08	Chiron Corporation	Modulation of inflammatory and metastatic processes
TW200538120A (en) *	2004-02-20	2005-12-01	Kirin Brewery	Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
MXPA06011423A (es)	2004-04-02	2007-01-23	Osi Pharm Inc	Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
HRP20110958T1 (hr)	2004-05-06	2012-01-31	Warner-Lambert Company Llc	4-fenilaminokinazolin-6-ilamidi
CA2567832A1 (en) *	2004-06-04	2005-12-15	Astrazeneca Ab	Quinazoline derivatives as erbb receptor tyrosine kinases
SE0401657D0 (sv)	2004-06-24	2004-06-24	Astrazeneca Ab	Chemical compounds
CN101014365B (zh)	2004-07-16	2011-04-13	辉瑞产品公司	使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
MY139689A (en)	2004-07-20	2009-10-30	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
JP4242911B2 (ja)	2004-08-26	2009-03-25	ファイザー・インク	プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
EP2311827A1 (en)	2004-08-28	2011-04-20	AstraZeneca AB	Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
MX2007006230A (es)	2004-11-30	2007-07-25	Amgen Inc	Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
ATE501148T1 (de)	2004-12-14	2011-03-15	Astrazeneca Ab	Pyrazolopyrimidinverbindungen als antitumormittel
ZA200705695B (en)	2004-12-21	2009-02-25	Astrazeneca Ab	Antibodies directed to angiopoietin-2 and uses thereof
GB0428526D0 (en)	2004-12-30	2005-02-09	Novartis Ag	Organic compounds
DK1845990T3 (da) *	2005-01-27	2012-01-02	Novartis Vaccines & Diagnostic	Behandling af metastaserede tumorer
DK2383268T3 (en)	2005-02-04	2015-09-14	Astrazeneca Ab	PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
AU2006216266C1 (en) *	2005-02-23	2010-08-26	Shionogi & Co., Ltd.	Quinazoline derivative having tyrosine kinase inhibitory activity
AU2006217738A1 (en) *	2005-02-26	2006-08-31	Astrazeneca Ab	Quinazoline derivatives as tyrosine kinase inhibitors
GB0504474D0 (en) *	2005-03-04	2005-04-13	Astrazeneca Ab	Chemical compounds
EP3300739A3 (en)	2005-03-31	2018-07-18	Agensys, Inc.	Antibodies and related molecules that bind to 161p2f10b proteins
EP1877444A2 (en)	2005-04-26	2008-01-16	Pfizer, Inc.	P-cadherin antibodies
JO2787B1 (en)	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
GB0508717D0 (en) *	2005-04-29	2005-06-08	Astrazeneca Ab	Chemical compounds
GB0508715D0 (en) *	2005-04-29	2005-06-08	Astrazeneca Ab	Chemical compounds
CN1858040B (zh) *	2005-05-08	2011-04-06	中国科学院上海药物研究所	5,8-二取代喹唑啉及其制备方法和用途
AU2006247803B2 (en)	2005-05-13	2011-12-22	Novartis Ag	Methods for treating drug resistant cancer
CA2608087C (en)	2005-05-17	2013-12-10	Gabriel Calvin	Methods for synthesizing heterocyclic compounds
TWI441637B (zh)	2005-05-18	2014-06-21	Array Biopharma Inc	Ｍｅｋ雜環抑制劑及其使用方法
EP2270000B1 (en)	2005-05-23	2015-07-29	Novartis AG	Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
RU2291706C1 (ru) *	2005-06-21	2007-01-20	Автономная некоммерческая организация Научно-технический центр "Фармбиопресс"	Применение флаволигнанов для подавления избыточной и патологической пролиферации эндотелия сосудов
CA2615650A1 (en)	2005-07-21	2007-01-25	Astrazeneca Ab	Novel piperidine derivatives
TW200738634A (en)	2005-08-02	2007-10-16	Astrazeneca Ab	New salt
US7566721B2 (en) *	2005-08-08	2009-07-28	Osi Pharmaceuticals, Inc.	Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
TW200738658A (en)	2005-08-09	2007-10-16	Astrazeneca Ab	Novel compounds
SI2447283T1 (sl)	2005-09-07	2015-12-31	Amgen Fremont Inc.	Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
ES2354457T3 (es)	2005-09-20	2011-03-15	Astrazeneca Ab	Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.
WO2007034143A1 (en) *	2005-09-20	2007-03-29	Astrazeneca Ab	Quinazoline derivatives as anticancer agents
AU2006292278B2 (en)	2005-09-20	2012-03-08	Osi Pharmaceuticals, Inc.	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JPWO2007034881A1 (ja)	2005-09-22	2009-03-26	大日本住友製薬株式会社	新規アデニン化合物
JPWO2007034882A1 (ja)	2005-09-22	2009-03-26	大日本住友製薬株式会社	新規アデニン化合物
WO2007034917A1 (ja)	2005-09-22	2007-03-29	Dainippon Sumitomo Pharma Co., Ltd.	新規なアデニン化合物
EP1939200A4 (en)	2005-09-22	2010-06-16	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
GB0519879D0 (en) *	2005-09-30	2005-11-09	Astrazeneca Ab	Chemical process
EP1937632A1 (en)	2005-10-06	2008-07-02	Astra Zeneca AB	Novel compounds
BRPI0618011A2 (pt)	2005-10-28	2011-08-16	Astrazeneca Ab	composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
CA2833706C (en)	2005-11-11	2014-10-21	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
DE602006021645D1 (de)	2005-11-15	2011-06-09	Array Biopharma Inc	Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
KR20080074143A (ko)	2005-11-29	2008-08-12	노파르티스 아게	퀴놀리논 제제
JP2009517451A (ja) *	2005-12-02	2009-04-30	アストラゼネカアクチボラグ	Ｅｒｂｂチロシンキナーゼの阻害剤として使用されるキナゾリン誘導体
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
EP1957499A1 (en) *	2005-12-02	2008-08-20	AstraZeneca AB	4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
TW200730512A (en)	2005-12-12	2007-08-16	Astrazeneca Ab	Novel compounds
PL1979001T3 (pl)	2005-12-13	2012-09-28	Medimmune Ltd	Białka wiążące specyficzne dla insulinopodobnych czynników wzrostu i ich zastosowania
ES2380683T3 (es)	2005-12-15	2012-05-17	Astrazeneca Ab	Difenil-Ã©teres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria
US8575164B2 (en) *	2005-12-19	2013-11-05	OSI Pharmaceuticals, LLC	Combination cancer therapy
US20070231298A1 (en) *	2006-03-31	2007-10-04	Cell Genesys, Inc.	Cytokine-expressing cancer immunotherapy combinations
TW200813091A (en)	2006-04-10	2008-03-16	Amgen Fremont Inc	Targeted binding agents directed to uPAR and uses thereof
EA200802058A1 (ru)	2006-05-09	2009-06-30	Пфайзер Продактс Инк.	Производные циклоалкиламинокислот и их фармацевтические композиции
US7741360B2 (en)	2006-05-26	2010-06-22	Astrazeneca Ab	Bi-aryl or aryl-heteroaryl substituted indoles
CL2007002225A1 (es)	2006-08-03	2008-04-18	Astrazeneca Ab	Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
DE102006037478A1 (de)	2006-08-10	2008-02-14	Merck Patent Gmbh	2-(Heterocyclylbenzyl)-pyridazinonderivate
JP5227321B2 (ja) *	2006-08-23	2013-07-03	クドスファーマシューティカルズリミテッド	Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
CA2663599A1 (en) *	2006-09-18	2008-03-27	Boehringer Ingelheim International Gmbh	Method for treating cancer harboring egfr mutations
CL2007003158A1 (es)	2006-11-02	2008-05-16	Astrazeneca Ab	Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
TW200825084A (en)	2006-11-14	2008-06-16	Astrazeneca Ab	New compounds 521
US7799954B2 (en)	2006-11-17	2010-09-21	Abraxis Bioscience, Llc	Dicarbonyl derivatives and methods of use
TW200831528A (en)	2006-11-30	2008-08-01	Astrazeneca Ab	Compounds
KR20090094460A (ko)	2006-12-19	2009-09-07	아스트라제네카 아베	무스카린 수용체 길항제로서 퀴누클리디놀 유도체
CL2008000191A1 (es)	2007-01-25	2008-08-22	Astrazeneca Ab	Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
JP5377332B2 (ja)	2007-02-06	2013-12-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
US20080190689A1 (en) *	2007-02-12	2008-08-14	Ballard Ebbin C	Inserts for engine exhaust systems
US8148532B2 (en)	2007-03-14	2012-04-03	Guoqing Paul Chen	Spiro substituted compounds as angiogenesis inhibitors
EP2138497A4 (en)	2007-03-20	2012-01-04	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
TW200902018A (en)	2007-03-20	2009-01-16	Dainippon Sumitomo Pharma Co	Novel adenine compound
UA99459C2 (en)	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
DE102007025718A1 (de)	2007-06-01	2008-12-04	Merck Patent Gmbh	Pyridazinonderivate
DE102007025717A1 (de)	2007-06-01	2008-12-11	Merck Patent Gmbh	Arylether-pyridazinonderivate
DE102007026341A1 (de)	2007-06-06	2008-12-11	Merck Patent Gmbh	Benzoxazolonderivate
UA100983C2 (ru)	2007-07-05	2013-02-25	Астразенека Аб	Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
DE102007038957A1 (de)	2007-08-17	2009-02-19	Merck Patent Gmbh	6-Thioxo-pyridazinderivate
DE102007041115A1 (de)	2007-08-30	2009-03-05	Merck Patent Gmbh	Thiadiazinonderivate
EP2185574B1 (en)	2007-09-07	2013-05-08	Agensys, Inc.	Antibodies and related molecules that bind to 24p4c12 proteins
MX2010003698A (es)	2007-10-04	2010-04-21	Astrazeneca Ab	Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide.
BRPI0818533B8 (pt)	2007-10-11	2021-05-25	Astrazeneca Ab	composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
TWI441820B (zh)	2007-12-19	2014-06-21	Genentech Inc	５－苯胺咪唑并吡啶及使用方法
MX2010006735A (es)	2007-12-21	2010-09-30	Medimmune Ltd	Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CA2708176A1 (en)	2007-12-21	2009-07-02	Genentech, Inc.	Azaindolizines and methods of use
DE102007061963A1 (de)	2007-12-21	2009-06-25	Merck Patent Gmbh	Pyridazinonderivate
EP2250173A1 (en) *	2008-01-18	2010-11-17	OSI Pharmaceuticals, Inc.	Imidazopyrazinol derivatives for the treatment of cancers
US7855204B2 (en) *	2008-01-22	2010-12-21	Concert Pharmaceuticals Inc.	Derivatives of gefitinib
US8609673B2 (en) *	2008-01-22	2013-12-17	Concert Pharmaceuticals, Inc.	Vandetanib derivatives
WO2009098061A1 (de)	2008-02-07	2009-08-13	Boehringer Ingelheim International Gmbh	Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2712990C (en)	2008-02-28	2016-09-27	Bayard R. Huck	Benzonaphthyridinyl compounds as protein kinase inhibitors and use thereof
DE102008019907A1 (de)	2008-04-21	2009-10-22	Merck Patent Gmbh	Pyridazinonderivate
MX2010012442A (es)	2008-05-13	2011-10-11	Astrazeneca Ab	Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
ES2396613T3 (es) *	2008-05-19	2013-02-22	OSI Pharmaceuticals, LLC	Imidazopirazinas e imidazotriazinas sustituidas
PT2297106E (pt)	2008-05-27	2014-09-29	Astrazeneca Ab	Derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doença mediados por pde4
DE102008025750A1 (de)	2008-05-29	2009-12-03	Merck Patent Gmbh	Dihydropyrazolderivate
DE102008028905A1 (de)	2008-06-18	2009-12-24	Merck Patent Gmbh	3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008029734A1 (de)	2008-06-23	2009-12-24	Merck Patent Gmbh	Thiazolyl-piperidinderivate
UY31952A (es)	2008-07-02	2010-01-29	Astrazeneca Ab	5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EP2313397B1 (de)	2008-08-08	2016-04-20	Boehringer Ingelheim International GmbH	Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102008037790A1 (de)	2008-08-14	2010-02-18	Merck Patent Gmbh	Bicyclische Triazolderivate
DE102008038221A1 (de)	2008-08-18	2010-02-25	Merck Patent Gmbh	7-Azaindolderivate
US8211911B2 (en)	2008-08-19	2012-07-03	Guoqing Paul Chen	Compounds as kinase inhibitors
CN102264763B (zh)	2008-09-19	2016-04-27	米迪缪尼有限公司	定向于dll4的抗体及其用途
CA2737597C (en)	2008-10-16	2017-03-14	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
DE102008052943A1 (de)	2008-10-23	2010-04-29	Merck Patent Gmbh	Azaindolderivate
WO2010067102A1 (en)	2008-12-09	2010-06-17	Astrazeneca Ab	Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
KR20110106355A (ko)	2008-12-11	2011-09-28	악센투아 파마슈투칼스 아베	제니스테인의 결정성 형태
US7863325B2 (en)	2008-12-11	2011-01-04	Axcentua Pharmaceuticals Ab	Crystalline genistein sodium salt dihydrate
US20100152197A1 (en)	2008-12-15	2010-06-17	Astrazeneca Ab	(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
ES2550101T3 (es)	2008-12-17	2015-11-04	Merck Patent Gmbh	Inhibidores de proteína quinasa de benzonaftiridinona tricíclica modificada con anillo C y su uso
DE102008063667A1 (de)	2008-12-18	2010-07-01	Merck Patent Gmbh	3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
US8853391B2 (en)	2008-12-18	2014-10-07	Merck Patent Gmbh	Tricyclic azaindoles
DE102008062825A1 (de)	2008-12-23	2010-06-24	Merck Patent Gmbh	3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
DE102008062826A1 (de)	2008-12-23	2010-07-01	Merck Patent Gmbh	Pyridazinonderivate
EP2379595A2 (en)	2008-12-23	2011-10-26	AstraZeneca AB	Targeted binding agents directed to 5 1 and uses thereof
DE102009003975A1 (de)	2009-01-07	2010-07-08	Merck Patent Gmbh	Benzothiazolonderivate
DE102009003954A1 (de)	2009-01-07	2010-07-08	Merck Patent Gmbh	Pyridazinonderivate
DE102009004061A1 (de)	2009-01-08	2010-07-15	Merck Patent Gmbh	Pyridazinonderivate
TW201920110A (zh)	2009-01-16	2019-06-01	美商艾克塞里克斯公司	包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
CA3014224C (en)	2009-02-05	2022-05-24	Immunogen, Inc.	Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
WO2010089580A1 (en)	2009-02-06	2010-08-12	Astrazeneca Ab	Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
SG172857A1 (en)	2009-02-09	2011-08-29	Supergen Inc	Pyrrolopyrimidinyl axl kinase inhibitors
WO2010092371A1 (en)	2009-02-10	2010-08-19	Astrazeneca Ab	Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
US20120189641A1 (en)	2009-02-25	2012-07-26	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US20110171124A1 (en)	2009-02-26	2011-07-14	Osi Pharmaceuticals, Inc.	In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010098866A1 (en)	2009-02-27	2010-09-02	Supergen, Inc.	Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
GB0905127D0 (en)	2009-03-25	2009-05-06	Pharminox Ltd	Novel prodrugs
UY32520A (es)	2009-04-03	2010-10-29	Astrazeneca Ab	Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
EP2421837A1 (en)	2009-04-20	2012-02-29	OSI Pharmaceuticals, LLC	Preparation of c-pyrazine-methylamines
WO2010129740A1 (en) *	2009-05-07	2010-11-11	Osi Pharmaceuticals, Inc.	Use of osi-906 for treating adrenocortical carcinoma
RU2404783C1 (ru) *	2009-05-20	2010-11-27	Общество с ограниченной ответственностью "Лигфарм"	Антиангиогенное лекарственное средство и способ его получения
US8389580B2 (en)	2009-06-02	2013-03-05	Duke University	Arylcyclopropylamines and methods of use
US20100317593A1 (en)	2009-06-12	2010-12-16	Astrazeneca Ab	2,3-dihydro-1h-indene compounds
SI2451445T1 (sl)	2009-07-06	2019-07-31	Boehringer Ingelheim International Gmbh	Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
SG177640A1 (en)	2009-07-13	2012-02-28	Genentech Inc	Diagnostic methods and compositions for treatment of cancer
GB0913342D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	Compounds - 801
WO2011014726A1 (en)	2009-07-31	2011-02-03	Osi Pharmaceuticals, Inc.	Mtor inhibitor and angiogenesis inhibitor combination therapy
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120157471A1 (en)	2009-09-01	2012-06-21	Pfizer Inc.	Benzimidazole derivatives
RU2012114094A (ru)	2009-09-11	2013-10-20	Дженентек, Инк.	Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
KR101557545B1 (ko)	2009-09-17	2015-10-06	에프. 호프만-라 로슈 아게	암 환자에서 진단 용도를 위한 방법 및 조성물
DE102009043260A1 (de)	2009-09-28	2011-04-28	Merck Patent Gmbh	Pyridinyl-imidazolonderivate
AU2010302420B2 (en)	2009-10-02	2013-07-04	Astrazeneca Ab	2-pyridone compounds used as inhibitors of neutrophil elastase
DE102009049679A1 (de)	2009-10-19	2011-04-21	Merck Patent Gmbh	Pyrazolopyrimidinderivate
WO2011048409A1 (en)	2009-10-20	2011-04-28	Astrazeneca Ab	Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8399460B2 (en)	2009-10-27	2013-03-19	Astrazeneca Ab	Chromenone derivatives
WO2011051478A1 (en)	2009-10-30	2011-05-05	Domain Therapeutics	Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
ES2442797T3 (es)	2009-11-18	2014-02-13	Neomed Institute	Compuestos de benzoimidazol y sus utilizaciones
EP3279215B1 (en)	2009-11-24	2020-02-12	MedImmune Limited	Targeted binding agents against b7-h1
JP2013512859A (ja)	2009-12-03	2013-04-18	大日本住友製薬株式会社	トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
AU2010333338A1 (en)	2009-12-14	2012-08-02	Merck Patent Gmbh	Sphingosine kinase inhibitors
DE102009058280A1 (de)	2009-12-14	2011-06-16	Merck Patent Gmbh	Thiazolderivate
WO2011073521A1 (en)	2009-12-15	2011-06-23	Petri Salven	Methods for enriching adult-derived endothelial progenitor cells and uses thereof
BR112012014884A2 (pt)	2009-12-17	2016-03-22	Merck Patent Gmbh	inibidores de esfingosina quinase
ES2654584T3 (es)	2010-01-15	2018-02-14	Suzhou Neupharma Co., Ltd	Ciertas entidades químicas, composiciones y métodos
US8198285B2 (en)	2010-01-19	2012-06-12	Astrazeneca Ab	Pyrazine derivatives
WO2011095807A1 (en)	2010-02-07	2011-08-11	Astrazeneca Ab	Combinations of mek and hh inhibitors
AR080154A1 (es)	2010-02-10	2012-03-14	Immunogen Inc	Anticuerpos cd20 y su utilizacion
ES2607806T5 (es)	2010-02-12	2024-10-07	Pfizer	Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
AU2011223643A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011114148A1 (en)	2010-03-17	2011-09-22	Astrazeneca Ab	4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2011153224A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Diagnostic methods and compositions for treatment of cancer
WO2011154677A1 (en)	2010-06-09	2011-12-15	Astrazeneca Ab	Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
GB201009801D0 (en)	2010-06-11	2010-07-21	Astrazeneca Ab	Compounds 950
CN103068851B (zh)	2010-06-16	2015-03-11	高等教育联邦系统-匹兹堡大学	内质蛋白的抗体及其用途
CN104634971A (zh)	2010-07-19	2015-05-20	霍夫曼-拉罗奇有限公司	鉴定响应抗癌疗法的可能性升高的患者的方法
WO2012010549A1 (en)	2010-07-19	2012-01-26	F. Hoffmann-La Roche Ag	Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG187592A1 (en)	2010-07-23	2013-03-28	Univ Boston	Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
UY33539A (es)	2010-08-02	2012-02-29	Astrazeneca Ab	Compuestos químicos alk
TWI535712B (zh)	2010-08-06	2016-06-01	阿斯特捷利康公司	化合物
DE102010034699A1 (de)	2010-08-18	2012-02-23	Merck Patent Gmbh	Pyrimidinderivate
US9018197B2 (en)	2010-08-28	2015-04-28	Suzhou Neupharma Co. Ltd.	Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
WO2012042421A1 (en)	2010-09-29	2012-04-05	Pfizer Inc.	Method of treating abnormal cell growth
GB201016442D0 (en)	2010-09-30	2010-11-17	Pharminox Ltd	Novel acridine derivatives
US9056865B2 (en)	2010-10-20	2015-06-16	Pfizer Inc.	Pyridine-2-derivatives as smoothened receptor modulators
DE102010048800A1 (de)	2010-10-20	2012-05-10	Merck Patent Gmbh	Chinoxalinderivate
DE102010049595A1 (de)	2010-10-26	2012-04-26	Merck Patent Gmbh	Chinazolinderivate
WO2012067268A1 (en)	2010-11-19	2012-05-24	Dainippon Sumitomo Pharma Co., Ltd.	Cyclic amide compounds and their use in the treatment of disease
WO2012067269A1 (en)	2010-11-19	2012-05-24	Dainippon Sumitomo Pharma Co., Ltd.	Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en)	2010-11-19	2012-05-24	Astrazeneca Ab	Benzylamine compounds as toll -like receptor 7 agonists
WO2012066335A1 (en)	2010-11-19	2012-05-24	Astrazeneca Ab	Phenol compounds als toll -like receptor 7 agonists
CN103370317B (zh)	2010-12-16	2015-10-07	阿斯利康(瑞典)有限公司	可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
WO2012080730A1 (en)	2010-12-17	2012-06-21	Astrazeneca Ab	Purine derivatives
BR112013015508B1 (pt)	2010-12-20	2022-04-05	Medimmune Limited	Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
EP3453714B1 (en)	2011-02-02	2020-11-04	Suzhou Neupharma Co., Ltd	Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
SI2675480T1 (sl)	2011-02-15	2019-05-31	Immunogen, Inc.	Metode priprave konjugatov
DK2675794T3 (da)	2011-02-17	2019-05-06	Cancer Therapeutics Crc Pty Ltd	Selektive fak-inhibitorer
WO2012110773A1 (en)	2011-02-17	2012-08-23	Cancer Therapeutics Crc Pty Limited	Fak inhibitors
WO2012116040A1 (en)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
GB201104267D0 (en)	2011-03-14	2011-04-27	Cancer Rec Tech Ltd	Pyrrolopyridineamino derivatives
WO2012142164A1 (en)	2011-04-12	2012-10-18	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
US8530470B2 (en)	2011-04-13	2013-09-10	Astrazeneca Ab	Chromenone derivatives
US20140178368A1 (en)	2011-04-19	2014-06-26	Leslie Lynne SHARP	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2012175991A1 (en)	2011-06-24	2012-12-27	Pharminox Limited	Fused pentacyclic anti - proliferative compounds
US20140227293A1 (en)	2011-06-30	2014-08-14	Trustees Of Boston University	Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
KR101946664B1 (ko)	2011-07-12	2019-02-11	아스트라제네카 아베	케모카인 수용체 조절제로서의 n-(6-((2r,3s)-3,4-디히드록시부탄-2-일옥시)-2-(4-플루오로벤질티오)피리미딘-4-일)-3-메틸아제티딘-1-술폰아미드
DK2734205T3 (en)	2011-07-21	2018-06-14	Tolero Pharmaceuticals Inc	Heterocyclic Protein Kinase Inhibitors
DK3686193T3 (da)	2011-07-27	2022-05-30	Astrazeneca Ab	2-(2,4,5-substitueret anilino)pyrimidinforbindelser
DE102011111400A1 (de)	2011-08-23	2013-02-28	Merck Patent Gmbh	Bicyclische heteroaromatische Verbindungen
WO2013032951A1 (en)	2011-08-26	2013-03-07	Neupharma, Inc.	Certain chemical entities, compositions, and methods
WO2013033250A1 (en)	2011-09-01	2013-03-07	Xiangping Qian	Certain chemical entities, compositions, and methods
AU2012308238B2 (en)	2011-09-14	2017-05-25	Neupharma, Inc.	Certain chemical entities, compositions, and methods
US9249110B2 (en)	2011-09-21	2016-02-02	Neupharma, Inc.	Substituted quinoxalines as B-raf kinase inhibitors
MD20140023A2 (ro)	2011-09-22	2014-06-30	Pfizer Inc.	Derivaţi de pirolpirimidină şi purină
US20140235573A1 (en)	2011-09-29	2014-08-21	The University Of Liverpool	Prevention and/or treatment of cancer and/or cancer metastasis
WO2013049701A1 (en)	2011-09-30	2013-04-04	Neupharma, Inc.	Certain chemical entities, compositions, and methods
ES2654160T3 (es)	2011-10-04	2018-02-12	Igem Therapeutics Limited	Anticuerpos de IgE anti-HMW-MAA
MX2014005570A (es)	2011-11-08	2014-05-30	Pfizer	El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
US20130178520A1 (en)	2011-12-23	2013-07-11	Duke University	Methods of treatment using arylcyclopropylamine compounds
EP2806874B1 (en)	2012-01-25	2017-11-15	Neupharma, Inc.	Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
US9409914B2 (en)	2012-01-28	2016-08-09	Merck Patent Gmbh	Triazolo[4,5-d]pyrimidine derivatives
CN104093722B (zh)	2012-02-09	2016-07-27	默克专利股份公司	作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
US9339503B2 (en)	2012-02-09	2016-05-17	Merck Patent Gmbh	Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
US9073944B2 (en)	2012-02-21	2015-07-07	Merck Patent Gmbh	Cyclic diaminopyrimidine derivatives
JP6479476B2 (ja)	2012-02-21	2019-03-06	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類
ES2606638T3 (es)	2012-02-21	2017-03-24	Merck Patent Gmbh	Derivados de furopiridina
EP2822948B1 (en)	2012-03-07	2016-04-06	Merck Patent GmbH	Triazolopyrazine derivatives
HRP20160908T1 (hr)	2012-03-28	2016-09-23	Merck Patent Gmbh	Biciklički derivati pirazinona
WO2013144532A1 (en)	2012-03-30	2013-10-03	Astrazeneca Ab	3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
KR101674784B1 (ko)	2012-04-05	2016-11-09	에프. 호프만-라 로슈 아게	인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
EP3453713B1 (en)	2012-04-29	2021-09-08	Neupharma, Inc.	Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
SG11201406997WA (en)	2012-05-04	2014-11-27	Merck Patent Gmbh	Pyrrolotriazinone derivatives
US9738724B2 (en)	2012-06-08	2017-08-22	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
GB201211021D0 (en)	2012-06-21	2012-08-01	Cancer Rec Tech Ltd	Pharmaceutically active compounds
EP3135690A1 (en)	2012-06-26	2017-03-01	Sutro Biopharma, Inc.	Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9624264B2 (en)	2012-07-24	2017-04-18	Merck Patent Gmbh	Hydroxystatin derivatives for the treatment of arthrosis
CA2881279C (en)	2012-08-07	2020-07-07	Merck Patent Gmbh	Pyridopyrimidine derivatives as protein kinase inhibitors
CN104507912B (zh)	2012-08-08	2016-09-28	默克专利股份公司	(氮杂-)异喹啉酮衍生物
HK1209105A1 (en)	2012-08-17	2016-03-24	Cancer Therapeutics Crc Pty Limited	Vegfr3 inhibitors
HK1211208A1 (zh)	2012-08-22	2016-05-20	Immunogen, Inc.	細胞毒性苯並二氮呯衍生物
SI2890402T1 (sl)	2012-08-31	2019-07-31	Sutro Biopharma, Inc.	Modificirane aminokisline vsebujoče acido skupino
WO2014041349A1 (en)	2012-09-12	2014-03-20	Cancer Therapeutics Crc Pty Ltd	Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
CN104812389B (zh)	2012-09-24	2020-07-17	润新生物公司	某些化学实体、组合物及方法
MX362855B (es)	2012-09-26	2019-02-20	Merck Patent Gmbh	Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
WO2014063205A1 (en)	2012-10-26	2014-05-01	The University Of Queensland	Use of endocytosis inhibitors and antibodies for cancer therapy
WO2014066955A1 (en)	2012-11-05	2014-05-08	Lindley Robyn Alice	Methods for determining the cause of somatic mutagenesis
US9725421B2 (en)	2012-11-12	2017-08-08	Neupharma, Inc.	Substituted quinoxalines as B-raf kinase inhibitors
US9732032B2 (en)	2012-11-16	2017-08-15	Merck Patent Gmbh	3-aminocyclopentane carboxamide derivatives
US9260426B2 (en)	2012-12-14	2016-02-16	Arrien Pharmaceuticals Llc	Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
KR102120513B1 (ko)	2013-01-31	2020-06-08	네오메드 인스티튜트	이미다조피리딘 화합물 및 이의 용도
WO2014127881A1 (de)	2013-02-25	2014-08-28	Merck Patent Gmbh	2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
HK1219423A1 (zh)	2013-02-28	2017-04-07	Immunogen, Inc.	包含细胞结合剂及细胞毒素剂的轭合物
HK1219422A1 (zh)	2013-02-28	2017-04-07	Immunogen, Inc.	包含细胞结合剂及细胞毒素剂的轭合物
EP2964648B1 (en)	2013-03-05	2016-11-16	Merck Patent GmbH	9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
PT2970205T (pt)	2013-03-14	2019-08-26	Tolero Pharmaceuticals Inc	Inibidores da jak2 e da alk2 e métodos para a sua utilização
US9937137B2 (en)	2013-03-15	2018-04-10	Neurocentria, Inc.	Magnesium compositions and uses thereof for cancers
WO2014161570A1 (en)	2013-04-03	2014-10-09	Roche Glycart Ag	Antibodies against human il17 and uses thereof
US9206188B2 (en)	2013-04-18	2015-12-08	Arrien Pharmaceuticals Llc	Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2014194030A2 (en)	2013-05-31	2014-12-04	Immunogen, Inc.	Conjugates comprising cell-binding agents and cytotoxic agents
EP3004073A1 (en)	2013-06-07	2016-04-13	Université catholique de Louvain	3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
SG11201510369WA (en)	2013-06-25	2016-01-28	Univ Canberra	Methods and compositions for modulating cancer stem cells
WO2015006555A2 (en)	2013-07-10	2015-01-15	Sutro Biopharma, Inc.	Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES3069593T3 (en)	2013-08-23	2026-06-09	Neupharma Inc	Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
CA2923765C (en)	2013-09-18	2021-06-29	University Of Canberra	Stem cell modulation ii
WO2015048852A1 (en)	2013-10-01	2015-04-09	The University Of Queensland	Kits and methods for diagnosis, screening, treatment and disease monitoring
EP3052102B1 (en)	2013-10-04	2019-12-04	Aptose Biosciences Inc.	Compositions for treating cancers
WO2015054658A1 (en)	2013-10-11	2015-04-16	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
GB201321146D0 (en) *	2013-11-29	2014-01-15	Cancer Rec Tech Ltd	Quinazoline compounds
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN104829542B (zh) *	2014-02-10	2018-02-02	中国科学院上海药物研究所	苯胺嘧啶类化合物、其制备方法和医药用途
GB201403536D0 (en)	2014-02-28	2014-04-16	Cancer Rec Tech Ltd	Inhibitor compounds
EP4012049A3 (en)	2014-04-04	2022-08-24	Crown Bioscience, Inc. (Taicang)	Methods for determining responsiveness to mek/erk inhibitors
WO2015155624A1 (en)	2014-04-10	2015-10-15	Pfizer Inc.	Dihydropyrrolopyrimidine derivatives
HRP20192056T1 (hr)	2014-04-30	2020-02-21	Pfizer Inc.	Derivati diheterocikla vezani na cikloalkil
WO2016001789A1 (en)	2014-06-30	2016-01-07	Pfizer Inc.	Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3177320B1 (en)	2014-07-31	2021-01-06	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Human monoclonal antibodies against epha4 and their use
CN105330653A (zh) *	2014-08-11	2016-02-17	石药集团中奇制药技术（石家庄）有限公司	喹唑啉衍生物
AU2015309686B2 (en)	2014-08-25	2020-05-14	Epiaxis Therapeutics Pty Ltd	Compositions for modulating cancer stem cells and uses therefor
CN107430126B (zh)	2014-11-17	2019-12-06	昆士兰大学	食管腺癌和巴雷特食管的糖蛋白生物标志物及其用途
WO2016097918A1 (en)	2014-12-18	2016-06-23	Pfizer Inc.	Pyrimidine and triazine derivatives and their use as axl inhibitors
MA41179A (fr)	2014-12-19	2017-10-24	Cancer Research Tech Ltd	Composés inhibiteurs de parg
GB201501870D0 (en)	2015-02-04	2015-03-18	Cancer Rec Tech Ltd	Autotaxin inhibitors
GB201502020D0 (en)	2015-02-06	2015-03-25	Cancer Rec Tech Ltd	Autotaxin inhibitory compounds
EP3270694A4 (en)	2015-02-17	2018-09-05	Neupharma, Inc.	Certain chemical entities, compositions, and methods
AU2016252609B2 (en)	2015-04-20	2022-06-30	Sumitomo Pharma Oncology, Inc.	Predicting response to alvocidib by mitochondrial profiling
CN107709344B (zh)	2015-05-01	2022-07-15	共晶制药股份有限公司	用于治疗黄病毒科病毒和癌症的核苷类似物
HUE045585T2 (hu)	2015-05-18	2020-01-28	Tolero Pharmaceuticals Inc	Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
GB201510019D0 (en)	2015-06-09	2015-07-22	Cancer Therapeutics Crc Pty Ltd	Compounds
WO2017009751A1 (en)	2015-07-15	2017-01-19	Pfizer Inc.	Pyrimidine derivatives
AU2016301315C1 (en)	2015-08-03	2022-07-07	Sumitomo Pharma Oncology, Inc.	Combination therapies for treatment of cancer
CN113336746A (zh)	2015-08-04	2021-09-03	常州千红生化制药股份有限公司	N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
EP3341496B1 (en)	2015-08-26	2021-02-24	GMDx Co Pty Ltd	Methods of detecting cancer recurrence
GB201516504D0 (en)	2015-09-17	2015-11-04	Astrazeneca Ab	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en)	2015-11-05	2015-12-23	Astrazeneca Ab	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2017096165A1 (en)	2015-12-03	2017-06-08	Agios Pharmaceuticals, Inc.	Mat2a inhibitors for treating mtap null cancer
AU2016377398B2 (en)	2015-12-23	2022-10-13	Repluca Pty Ltd	Nucleic acid oligomers and uses therefor
AU2017212739B2 (en)	2016-01-27	2024-03-21	Sutro Biopharma, Inc.	Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
JP7341451B2 (ja)	2016-02-01	2023-09-11	エピアクシスセラピューティクスプロプライアタリーリミティド	タンパク質性化合物とその利用
GB201604182D0 (en)	2016-03-11	2016-04-27	Astrazeneca Ab	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PE20181895A1 (es)	2016-03-21	2018-12-11	Astrazeneca Ab	Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer
US20190119270A1 (en)	2016-04-07	2019-04-25	Astrazeneca Ab	N-Oxide Compound and Its Use in Treating Cancer
HRP20221051T8 (hr)	2016-04-15	2023-07-21	Cancer Research Technology Limited	Heterociklički spojevi kao inhibitori ret kinaze
GB2554333A (en)	2016-04-26	2018-04-04	Big Dna Ltd	Combination therapy
GB201608227D0 (en)	2016-05-11	2016-06-22	Astrazeneca Ab	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
ES2925564T3 (es)	2016-07-29	2022-10-18	Rapt Therapeutics Inc	Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
CN109843858B (zh)	2016-08-15	2023-05-05	润新生物公司	某些化学实体、组合物及方法
CA3035081A1 (en)	2016-09-02	2018-03-08	Dana-Farber Cancer Institute, Inc.	Composition and methods of treating b cell disorders
AU2017332839B2 (en)	2016-09-22	2021-11-11	Cancer Research Technology Limited	Preparation and uses of pyrimidinone derivatives
GB201617103D0 (en)	2016-10-07	2016-11-23	Cancer Research Technology Limited	Compound
WO2018094275A1 (en)	2016-11-18	2018-05-24	Tolero Pharmaceuticals, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018106606A1 (en)	2016-12-05	2018-06-14	Apros Therapeutics, Inc.	Pyrimidine compounds containing acidic groups
US10786502B2 (en)	2016-12-05	2020-09-29	Apros Therapeutics, Inc.	Substituted pyrimidines containing acidic groups as TLR7 modulators
CA3047557A1 (en)	2016-12-19	2018-06-28	Tolero Pharmaceuticals, Inc.	Profiling peptides and methods for sensitivity profiling
DK3558997T3 (da)	2016-12-20	2021-04-19	Astrazeneca Ab	Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
US11111245B2 (en)	2017-02-01	2021-09-07	Aucentra Therapeutics Pty Ltd	Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
US10703723B2 (en)	2017-03-09	2020-07-07	Truly Translational Sweden Ab	Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
JOP20190209A1 (ar)	2017-03-16	2019-09-12	Astrazeneca Ab	مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
GB201704325D0 (en)	2017-03-17	2017-05-03	Argonaut Therapeutics Ltd	Compounds
GB201705971D0 (en)	2017-04-13	2017-05-31	Cancer Res Tech Ltd	Inhibitor compounds
CN108864079B (zh)	2017-05-15	2021-04-09	深圳福沃药业有限公司	一种三嗪化合物及其药学上可接受的盐
EP3630291B9 (en)	2017-05-26	2024-05-29	Cancer Research Technology Limited	Benzimidazolone derived inhibitors of bcl6
EP3630749B9 (en)	2017-05-26	2024-05-29	Cancer Research Technology Limited	2-quinolone derived inhibitors of bcl6
ES2897200T3 (es)	2017-05-31	2022-02-28	Amplio Pharma Ab	Una composición farmacéutica que comprende una combinación de metotrexato y novobiocina, y el uso de la composición en terapia
WO2019006157A1 (en) *	2017-06-28	2019-01-03	Vanderbilt University	Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3648797A1 (en)	2017-07-05	2020-05-13	EPOS-Iasis Research and Development, Ltd	Multifunctional conjugates
EP3658588A1 (en)	2017-07-26	2020-06-03	Sutro Biopharma, Inc.	Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
WO2019025099A1 (en)	2017-08-01	2019-02-07	Merck Patent Gmbh	THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
CN111278840B (zh)	2017-08-18	2023-11-17	癌症研究科技有限公司	吡咯并[2，3-b]吡啶化合物及其治疗癌症的用途
KR20200043433A (ko)	2017-08-21	2020-04-27	메르크 파텐트 게엠베하	아데노신 수용체 길항제로서의 벤즈이미다졸 유도체
KR20200043434A (ko)	2017-08-21	2020-04-27	메르크 파텐트 게엠베하	아데노신 수용체 길항제로서의 퀴녹살린 유도체
JP7196160B2 (ja)	2017-09-12	2022-12-26	スミトモファーマオンコロジー，インコーポレイテッド	Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
MA50265A (fr)	2017-09-18	2020-07-29	Sutro Biopharma Inc	Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
CN111344293A (zh)	2017-09-20	2020-06-26	阿斯利康(瑞典)有限公司	1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
TWI702205B (zh)	2017-10-06	2020-08-21	俄羅斯聯邦商拜奧卡德聯合股份公司	表皮生長因子受體抑制劑
US20200237766A1 (en)	2017-10-13	2020-07-30	Tolero Pharmaceuticals, Inc.	Pkm2 activators in combination with reactive oxygen species for treatment of cancer
AU2018360766B2 (en)	2017-11-06	2024-09-19	Rapt Therapeutics, Inc.	Anticancer agents
ES2965337T3 (es)	2017-11-23	2024-04-12	Medac Ges Fuer Klinische Spezialpraeparate Mbh	Composición farmacéutica para administración oral que contiene sulfasalazina y/o una sal orgánica de sulfasalazina, proceso de producción y uso
EP3489222A1 (en)	2017-11-23	2019-05-29	medac Gesellschaft für klinische Spezialpräparate mbH	Sulfasalazine salts, production processes and uses
US11325900B2 (en)	2018-01-15	2022-05-10	Aucentra Holdings Pty Ltd	5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en)	2018-01-24	2018-03-07	Univ Oxford Innovation Ltd	Compounds
US10683280B2 (en)	2018-01-26	2020-06-16	Rapt Therapeutics, Inc.	Chemokine receptor modulators and uses thereof
PL3749310T3 (pl)	2018-02-08	2026-05-25	Neupharma, Inc.	Określone jednostki chemiczne, kompozycje i sposoby
WO2019175093A1 (en)	2018-03-12	2019-09-19	Astrazeneca Ab	Method for treating lung cancer
IL296734B2 (en)	2018-04-13	2025-06-01	The Institute Of Cancer Res Royal Cancer Hospital	Bcl6 inhibitors
MX2020011344A (es)	2018-04-27	2021-02-09	Spruce Biosciences Inc	Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
GB201809102D0 (en)	2018-06-04	2018-07-18	Univ Oxford Innovation Ltd	Compounds
JP7351859B2 (ja)	2018-06-04	2023-09-27	アプロスセラピューティクス，インコーポレイテッド	Ｔｌｒ７の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
EP3802544A1 (en)	2018-06-05	2021-04-14	RAPT Therapeutics, Inc.	Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
GB201810092D0 (en)	2018-06-20	2018-08-08	Ctxt Pty Ltd	Compounds
GB201810581D0 (en)	2018-06-28	2018-08-15	Ctxt Pty Ltd	Compounds
KR20210038906A (ko)	2018-07-26	2021-04-08	스미토모 다이니폰 파마 온콜로지, 인크.	비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
WO2020052688A1 (en)	2018-09-14	2020-03-19	Suzhou Zanrong Pharma Limited	1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF
JP2022500454A (ja)	2018-09-17	2022-01-04	ストロバイオファーマインコーポレーテッド	抗葉酸受容体抗体コンジュゲートによる併用療法
HRP20240293T1 (hr)	2018-09-18	2024-05-24	F. Hoffmann - La Roche Ag	Derivati kinazolina kao protutumorska sredstva
US11084829B2 (en)	2018-09-24	2021-08-10	Rapt Therapeutics, Inc.	Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
EP3870294A1 (en)	2018-10-25	2021-09-01	Merck Patent GmbH	5-azaindazole derivatives as adenosine receptor antagonists
KR20210083287A (ko)	2018-10-25	2021-07-06	메르크 파텐트 게엠베하	아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
DK3880678T3 (da)	2018-11-13	2025-06-10	Glaxosmithkline Intellectual Property No 3 Ltd	Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat
GB201819126D0 (en)	2018-11-23	2019-01-09	Cancer Research Tech Ltd	Inhibitor compounds
US11034710B2 (en)	2018-12-04	2021-06-15	Sumitomo Dainippon Pharma Oncology, Inc.	CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CA3124730A1 (en)	2018-12-25	2020-07-02	Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences	Small rna medicament for prevention and treatment of inflammation-related diseases and combinations thereof
AR117844A1 (es)	2019-01-22	2021-09-01	Merck Patent Gmbh	Derivados de tiazolopiridina como antagonistas del receptor de adenosina
HUE072069T2 (hu)	2019-02-12	2025-10-28	Sumitomo Pharma America Inc	2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
CA3131312A1 (en)	2019-02-25	2020-09-03	Bellus Health Cough Inc.	Treatment with p2x3 modulators
US11033547B2 (en)	2019-03-07	2021-06-15	Merck Patent Gmbh	Carboxamide-pyrimidine derivatives as SHP2 antagonists
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
AU2020245437A1 (en)	2019-03-22	2021-09-30	Sumitomo Pharma Oncology, Inc.	Compositions comprising PKM2 modulators and methods of treatment using the same
AU2020245902B2 (en)	2019-03-28	2025-01-02	Amplia Therapeutics Limited	A salt and crystal form of a FAK inhibitor
CN111747950B (zh)	2019-03-29	2024-01-23	深圳福沃药业有限公司	用于治疗癌症的嘧啶衍生物
JP2022526159A (ja)	2019-03-29	2022-05-23	アストラゼネカ・アクチエボラーグ	非小細胞肺がんの治療に使用するためのオシメルチニブ
WO2020201773A1 (en)	2019-04-05	2020-10-08	Storm Therapeutics Ltd	Mettl3 inhibitory compounds
CN113646049B (zh)	2019-04-08	2024-08-13	默克专利有限公司	作为shp2拮抗剂的嘧啶酮衍生物
GB201905328D0 (en)	2019-04-15	2019-05-29	Azeria Therapeutics Ltd	Inhibitor compounds
US20220362394A1 (en)	2019-05-03	2022-11-17	Sutro Biopharma, Inc.	Anti-bcma antibody conjugates
GB201908885D0 (en)	2019-06-20	2019-08-07	Storm Therapeutics Ltd	Therapeutic compounds
JP2022545930A (ja)	2019-08-31	2022-11-01	上海奕拓醫藥科技有限責任公司	Ｆｇｆｒ阻害剤とするピラゾール類誘導体及びその調製方法
IL291436B1 (en)	2019-09-20	2026-07-01	Ideaya Biosciences Inc	History of indole and indazole sulfonamido 4-mutates as PARG inhibitors
GB201913988D0 (en)	2019-09-27	2019-11-13	Celleron Therapeutics Ltd	Novel treatment
GB201914860D0 (en)	2019-10-14	2019-11-27	Cancer Research Tech Ltd	Inhibitor compounds
GB201915831D0 (en)	2019-10-31	2019-12-18	Cancer Research Tech Ltd	Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en)	2019-10-31	2019-12-18	Cancer Research Tech Ltd	Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en)	2019-10-31	2019-12-18	Cancer Research Tech Ltd	Compounds, compositions and therapeutic uses thereof
US12195458B2 (en)	2019-12-02	2025-01-14	Storm Therapeutics Limited	Polyheterocyclic compounds as METTL3 inhibitors
WO2021155006A1 (en)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibitors of cyclin-dependent kinases and uses thereof
US20230095053A1 (en)	2020-03-03	2023-03-30	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
GB202004960D0 (en)	2020-04-03	2020-05-20	Kinsenus Ltd	Inhibitor compounds
CN115666561A (zh)	2020-05-06	2023-01-31	澳升医药公司	Cns的增殖性疾病的治疗
GB202012969D0 (en)	2020-08-19	2020-09-30	Univ Of Oxford	Inhibitor compounds
WO2022074379A1 (en)	2020-10-06	2022-04-14	Storm Therapeutics Limited	Mettl3 inhibitory compounds
US20240101589A1 (en)	2020-10-08	2024-03-28	Strom Therapeutics Limited	Inhibitors of mettl3
EP3992191A1 (en)	2020-11-03	2022-05-04	Deutsches Krebsforschungszentrum	Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
GB202102895D0 (en)	2021-03-01	2021-04-14	Cambridge Entpr Ltd	Novel compounds, compositions and therapeutic uses thereof
US11918582B2 (en)	2021-03-15	2024-03-05	Rapt Therapeutics, Inc.	Pyrazole pyrimidine compounds and uses thereof
AU2021433713A1 (en)	2021-03-17	2023-09-28	Suzhou Zanrong Pharma Limited	Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN117396231A (zh)	2021-04-30	2024-01-12	新基公司	使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
US20250281633A1 (en)	2021-05-03	2025-09-11	Merck Patent Gmbh	Her2 targeting fc antigen binding fragment-drug conjugates
MX2023013690A (es)	2021-05-17	2024-01-30	Hk Inno N Corp	Derivado de benzamida, metodo para preparar el mismo, y composicion farmaceutica para la prevencion o tratamiento del cancer que contiene el mismo como ingrediente activo.
US20240226319A1 (en)	2021-05-25	2024-07-11	Merck Patent Gmbh	Egfr targeting fc antigen binding fragment-drug conjugates
GB202107907D0 (en)	2021-06-02	2021-07-14	Storm Therapeutics Ltd	Combination therapies
GB202108383D0 (en)	2021-06-11	2021-07-28	Argonaut Therapeutics Ltd	Compounds useful in the treatment or prevention of a prmt5-mediated disorder
US20250002491A1 (en)	2021-10-04	2025-01-02	Forx Therapeutics Ag	N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CA3225500A1 (en)	2021-10-04	2023-04-13	Ulrich Luecking	Parg inhibitory compounds
CR20240163A (es)	2021-10-20	2024-06-12	Hoffmann La Roche	Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas
AU2023205435A1 (en)	2022-01-10	2024-08-22	Cancer Research Horizons	Substituted heterocycles as hset inhibitors
GB202202199D0 (en)	2022-02-18	2022-04-06	Cancer Research Tech Ltd	Compounds
WO2023175184A1 (en)	2022-03-17	2023-09-21	Forx Therapeutics Ag	2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en)	2022-03-17	2023-09-21	Forx Therapeutics Ag	2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023186881A1 (en)	2022-03-29	2023-10-05	Baden-Württemberg Stiftung Ggmbh	P38 map kinase inhibitors for use in the treatment of colorectal cancer
GB202204935D0 (en)	2022-04-04	2022-05-18	Cambridge Entpr Ltd	Nanoparticles
CA3255429A1 (en)	2022-04-06	2023-10-12	Rapt Therapeutics, Inc.	Chemokine Receptor Modulators and Their Uses
IL316261A (en)	2022-04-28	2024-12-01	Danatlas Pharmaceuticals Co Ltd	Tricyclic and heterocyclic derivatives, preparations and uses thereof
GB202209404D0 (en)	2022-06-27	2022-08-10	Univ Of Sussex	Compounds
IL317782A (en)	2022-06-30	2025-02-01	Sutro Biopharma Inc	Anti-ROR1 antibodies and conjugates thereof, compositions containing anti-ROR1 antibodies or conjugates thereof, and methods for preparing and using anti-ROR1 antibodies and conjugates thereof
EP4565592A1 (en)	2022-08-01	2025-06-11	Neupharma, Inc.	Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213166D0 (en)	2022-09-08	2022-10-26	Cambridge Entpr Ltd	Novel compounds, compositions and therapeutic uses thereof
GB202213164D0 (en)	2022-09-08	2022-10-26	Cambridge Entpr Ltd	Novel compounds, compositions and therapeutic uses thereof
GB202213167D0 (en)	2022-09-08	2022-10-26	Cambridge Entpr Ltd	Novel compounds, compositions and therapeutic uses thereof
GB202213162D0 (en)	2022-09-08	2022-10-26	Cambridge Entpr Ltd	Prodrugs
GB202213163D0 (en)	2022-09-08	2022-10-26	Cambridge Entpr Ltd	Novel compounds, compositions and therapeutic uses thereof
IL320031A (en)	2022-10-03	2025-06-01	Forx Therapeutics Ag	Parg inhibitory compound
WO2024094962A1 (en)	2022-11-02	2024-05-10	Cancer Research Technology Limited	Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
EP4612148A1 (en)	2022-11-02	2025-09-10	Cancer Research Technology Limited	2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
CN120265629A (zh)	2022-11-07	2025-07-04	默克专利股份公司	被取代的双环和三环hset抑制剂
GB202218672D0 (en)	2022-12-12	2023-01-25	Storm Therapeutics Ltd	Inhibitory compounds
JP2026504889A (ja)	2023-01-18	2026-02-10	アンテンジーン・ディスカバリー・リミテッド	Ｐｒｍｔ５阻害化合物およびその使用
WO2024173453A1 (en)	2023-02-14	2024-08-22	Ideaya Biosciences, Inc.	Heteroaryl-substituted imidazopyridine compounds
WO2024173514A1 (en)	2023-02-14	2024-08-22	Ideaya Biosciences, Inc.	Amide and ester-substituted imidazopyridine compounds
WO2024173530A1 (en)	2023-02-14	2024-08-22	Ideaya Biosciences, Inc.	Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173524A1 (en)	2023-02-14	2024-08-22	Ideaya Biosciences, Inc.	Heteroaryl-substituted benzimidazole compounds
KR20250153866A (ko)	2023-03-10	2025-10-27	브레이크포인트 테라퓨틱스 게엠베하	Dna 중합효소 세타 억제제
EP4434972A1 (en)	2023-03-22	2024-09-25	Eberhard-Karls-Universität Tübingen	Atm kinase inhibitors
WO2024209035A1 (en)	2023-04-05	2024-10-10	Forx Therapeutics Ag	Parg inhibitory compounds
GB2631507A (en)	2023-07-04	2025-01-08	Univ Liverpool	Compositions
GB2631509A (en)	2023-07-04	2025-01-08	Univ Liverpool	Compositions
WO2025043017A1 (en) *	2023-08-21	2025-02-27	University Of Central Florida Research Foundation, Inc.	Efficient identification of new small molecules targeting succinate dehydrogenase
WO2025046148A1 (en)	2023-09-01	2025-03-06	Forx Therapeutics Ag	Novel parg inhibitors
WO2025056923A1 (en)	2023-09-15	2025-03-20	Cambridge Enterprise Limited	Combination therapy
WO2025073792A1 (en)	2023-10-02	2025-04-10	Forx Therapeutics Ag	Wrn inhibitory compounds
GB202315149D0 (en)	2023-10-03	2023-11-15	Celleron Therapeutics Ltd	Combination therapy
KR20260084620A (ko)	2023-10-03	2026-06-05	포알엑스 테라퓨틱스 아게	Parg 억제 화합물
US12540197B2 (en)	2023-10-13	2026-02-03	Sutro Biopharma, Inc.	Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
GB202316595D0 (en)	2023-10-30	2023-12-13	Storm Therapeutics Ltd	Inhibitory compounds
GB202316683D0 (en)	2023-10-31	2023-12-13	Storm Therapeutics Ltd	Inhibitory compounds
WO2025093755A1 (en)	2023-11-01	2025-05-08	Forx Therapeutics Ag	Novel parc inhibitors
GB202317368D0 (en)	2023-11-13	2023-12-27	Breakpoint Therapeutics Gmbh	Novel compounds, compositions and therapeutic uses thereof
WO2025104443A1 (en)	2023-11-14	2025-05-22	Storm Therapeutics Ltd	Inhibitory compounds
WO2025114480A1 (en)	2023-11-28	2025-06-05	Forx Therapeutics Ag	Wrn inhibitory compounds
IL328906A (en)	2023-12-18	2026-08-01	Ideaya Biosciences Inc	Chemical compounds and their uses
GB202319863D0 (en)	2023-12-21	2024-02-07	Breakpoint Therapeutics Gmbh	Movel compounds, compositions and therapeutics uses thereof
GB202319864D0 (en)	2023-12-21	2024-02-07	Breakpoint Therapeutics Gmbh	Novel compounds, compositions and therapeutic uses thereof
WO2025133395A1 (en)	2023-12-22	2025-06-26	Forx Therapeutics Ag	Bicyclic (hetero)arylene wrn inhibitory compounds
WO2025133396A1 (en)	2023-12-22	2025-06-26	Forx Therapeutics Ag	Novel bicyclo heteroaryl parg inhibitors
WO2025191176A1 (en)	2024-03-14	2025-09-18	Forx Therapeutics Ag	Wrn inhibitory compounds
NL2037411B1 (en)	2024-04-08	2025-10-31	Univ Leiden	Protac compounds
WO2025250825A1 (en)	2024-05-30	2025-12-04	Sutro Biopharma, Inc.	Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
GB202407738D0 (en)	2024-05-31	2024-07-17	Storm Therapeutics Ltd	Inhibitory compounds
WO2025262192A1 (en)	2024-06-21	2025-12-26	Breakpoint Therapeutics Gmbh	Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
WO2026003380A1 (en)	2024-06-28	2026-01-02	Forx Therapeutics Ag	Wrn inhibitory compounds
WO2026022150A1 (en)	2024-07-22	2026-01-29	Forx Therapeutics Ag	Parg inhibitory compounds
WO2026043823A2 (en)	2024-08-19	2026-02-26	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026062066A1 (en)	2024-09-17	2026-03-26	Forx Therapeutics Ag	Compounds inducing parg degradation
WO2026080697A1 (en)	2024-10-09	2026-04-16	Sutro Biopharma, Inc.	Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use
GB202416489D0 (en)	2024-11-08	2024-12-25	Institute Of Cancer Res Royal Cancer Hospital The	Therapeutic bifunctional agents
WO2026125304A1 (en)	2024-12-11	2026-06-18	Merck Patent Gmbh	Carboxylic acids as dhx8/16 inhibitors
WO2026132784A2 (en)	2024-12-19	2026-06-25	Storm Therapeutics Ltd	Inhibitory compounds
CN119912427A (zh) *	2025-01-02	2025-05-02	浙江工业大学	2-溴-4-（哌啶基甲基）吡啶的合成方法
WO2026165269A1 (en)	2025-01-29	2026-08-06	Sutro Biopharma, Inc.	Anti-b7-h3 antibodies, compositions comprising anti-b7-h3 antibodies and methods of making and using anti- b7-h3 antibodies

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3266990A (en) *	1963-09-24	1966-08-16	Warner Lambert Pharmaceutical	Derivatives of quinazoline
JPS5538325A (en) *	1978-09-11	1980-03-17	Sankyo Co Ltd	4-anilinoquinazoline derivative and its preparation
US4343940A (en) *	1979-02-13	1982-08-10	Mead Johnson & Company	Anti-tumor quinazoline compounds
GB2160201B (en) *	1984-06-14	1988-05-11	Wyeth John & Brother Ltd	Quinazoline and cinnoline derivatives
EP0326307B1 (en) *	1988-01-23	1994-08-17	Kyowa Hakko Kogyo Co., Ltd.	Novel pyridazinone derivatives and pharmaceutical preparations containing them
IL89029A (en) *	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5411963A (en) *	1988-01-29	1995-05-02	Dowelanco	Quinazoline derivatives
ES2071484T3 (es) *	1991-02-20	1995-06-16	Pfizer	Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
DE4105518A1 (de)	1991-02-22	1992-08-27	Basf Ag	Sulfonylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung
DE69222637T2 (de) *	1991-05-10	1998-02-26	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5721237A (en) *	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) *	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
DE4208254A1 (de) *	1992-03-14	1993-09-16	Hoechst Ag	Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5270466A (en) *	1992-06-11	1993-12-14	American Cyanamid Company	Substituted quinazoline fungicidal agents
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) *	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
DE4309613C2 (de)	1993-03-24	1996-10-17	Bfi Entsorgungstech	Vorrichtung zum Verteilen fester Abfallmaterialien auf einem Transportband
GB9314893D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
WO1995006648A1 (fr) *	1993-09-03	1995-03-09	Kyowa Hakko Kogyo Co., Ltd.	Derive d'imidazoquinazoline
GB9325217D0 (en) *	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
CA2183655C (en) *	1994-02-23	2001-03-06	Lee D. Arnold	4-polycyclic amino-substituted quinazoline derivatives
WO1995024190A2 (en) *	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
ES2109796T3 (es) *	1994-05-03	1998-01-16	Ciba Geigy Ag	Derivados de pirrolopirimidilo con efecto antiproliferante.
DE19503151A1 (de) *	1995-02-01	1996-08-08	Thomae Gmbh Dr K	Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW414798B (en) *	1994-09-07	2000-12-11	Thomae Gmbh Dr K	Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (el) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
WO1996029331A1 (de) *	1995-03-20	1996-09-26	Dr. Karl Thomae Gmbh	Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE446955T1 (de) *	1995-03-30	2009-11-15	Pfizer Prod Inc	Chinazolinone derivate
DE19513330A1 (de) *	1995-04-03	1996-10-10	Schering Ag	Neues Verfahren zur Herstellung von Nucleosiden
JP4249804B2 (ja) *	1995-04-03	2009-04-08	ノバルティス・アクチエンゲゼルシャフト	ピラゾール誘導体およびその製造法
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
EP0824525B1 (en) *	1995-04-27	2001-06-13	AstraZeneca AB	Quinazoline derivatives
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
IL117923A (en) *	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
JPH10506126A (ja) *	1995-05-12	1998-06-16	ニューロゲンコーポレイション	新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス
JPH11507052A (ja) *	1995-06-07	1999-06-22	スージェン・インコーポレーテッド	キナゾリンおよび医薬組成物
CA2223081C (en) *	1995-06-07	2001-03-06	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
PL188959B1 (pl) *	1995-07-06	2005-05-31	Novartis Ag	Pirolopirymidyny i sposoby ich wytwarzania
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
AR004010A1 (es) *	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
GB9520822D0 (en) *	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds
HUP9801177A3 (en) *	1995-11-14	1998-11-30	Pharmacia & Upjohn Spa	Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
US5760041A (en) *	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
EP0837063A1 (en) *	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazoline derivatives

1996
- 1996-11-25 GB GBGB9624482.7A patent/GB9624482D0/en active Pending
- 1996-12-13 BR BR9612043-6A patent/BR9612043A/pt not_active IP Right Cessation
- 1996-12-13 AU AU11061/97A patent/AU712370B2/en not_active Ceased
- 1996-12-13 HU HU9901243A patent/HUP9901243A3/hu unknown
- 1996-12-13 SI SI9630354T patent/SI0873319T1/xx unknown
- 1996-12-13 CZ CZ19981882A patent/CZ291100B6/cs not_active IP Right Cessation
- 1996-12-13 RU RU98113300/04A patent/RU2194701C2/ru not_active IP Right Cessation
- 1996-12-13 PT PT96941787T patent/PT873319E/pt unknown
- 1996-12-13 EP EP96941787A patent/EP0873319B1/en not_active Expired - Lifetime
- 1996-12-13 KR KR1019980704613A patent/KR100530311B1/ko not_active Expired - Fee Related
- 1996-12-13 DE DE69614147T patent/DE69614147T2/de not_active Expired - Lifetime
- 1996-12-13 PL PL327310A patent/PL192309B1/pl not_active IP Right Cessation
- 1996-12-13 WO PCT/GB1996/003075 patent/WO1997022596A1/en not_active Ceased
- 1996-12-13 DK DK96941787T patent/DK0873319T3/da active
- 1996-12-13 JP JP52256897A patent/JP4291413B2/ja not_active Expired - Fee Related
- 1996-12-13 NZ NZ324007A patent/NZ324007A/xx not_active IP Right Cessation
- 1996-12-13 CN CNB961991100A patent/CN1133625C/zh not_active Expired - Fee Related
- 1996-12-13 TR TR1998/01115T patent/TR199801115T2/xx unknown
- 1996-12-13 CA CA002237005A patent/CA2237005C/en not_active Expired - Fee Related
- 1996-12-13 ES ES96941787T patent/ES2162656T3/es not_active Expired - Lifetime
- 1996-12-13 IL IL12492596A patent/IL124925A0/xx not_active IP Right Cessation
- 1996-12-13 SK SK828-98A patent/SK282443B6/sk not_active IP Right Cessation
- 1996-12-13 AT AT96941787T patent/ATE203524T1/de active
- 1996-12-17 TW TW085115569A patent/TW411274B/zh not_active IP Right Cessation
- 1996-12-17 US US08/768,887 patent/US5962458A/en not_active Expired - Lifetime
- 1996-12-17 MY MYPI96005309A patent/MY132405A/en unknown
1998
- 1998-05-28 MX MX9804247A patent/MX9804247A/es unknown
- 1998-06-17 NO NO19982784A patent/NO311358B1/no not_active IP Right Cessation
- 1998-12-02 US US09/203,764 patent/US6071921A/en not_active Expired - Lifetime
2000
- 2000-02-09 US US09/500,470 patent/US6258951B1/en not_active Expired - Lifetime
2001
- 2001-06-11 US US09/877,005 patent/US6362336B1/en not_active Expired - Lifetime
- 2001-10-19 GR GR20010401823T patent/GR3036954T3/el unknown

Also Published As

Publication number	Publication date
CA2237005C (en)	2006-03-14
JP4291413B2 (ja)	2009-07-08
DK0873319T3 (da)	2001-10-22
DE69614147D1 (de)	2001-08-30
US6258951B1 (en)	2001-07-10
DE69614147T2 (de)	2002-03-21
TW411274B (en)	2000-11-11
NO982784L (no)	1998-08-17
HUP9901243A2 (hu)	1999-08-30
CZ188298A3 (cs)	1998-09-16
CN1205694A (zh)	1999-01-20
NO982784D0 (no)	1998-06-17
US6071921A (en)	2000-06-06
AU1106197A (en)	1997-07-14
ATE203524T1 (de)	2001-08-15
CN1133625C (zh)	2004-01-07
MY132405A (en)	2007-10-31
KR20000064455A (ko)	2000-11-06
IL124925A0 (en)	1999-01-26
PT873319E (pt)	2002-01-30
AU712370B2 (en)	1999-11-04
SK82898A3 (en)	1998-11-04
US6362336B1 (en)	2002-03-26
PL192309B1 (pl)	2006-09-29
BR9612043A (pt)	1999-12-28
EP0873319A1 (en)	1998-10-28
WO1997022596A1 (en)	1997-06-26
CZ291100B6 (cs)	2002-12-11
US20020032208A1 (en)	2002-03-14
ES2162656T3 (es)	2002-01-01
TR199801115T2 (xx)	1998-08-21
US5962458A (en)	1999-10-05
SI0873319T1 (en)	2002-02-28
RU2194701C2 (ru)	2002-12-20
JP2000515114A (ja)	2000-11-14
PL327310A1 (en)	1998-12-07
KR100530311B1 (ko)	2006-03-09
HUP9901243A3 (en)	2001-11-28
CA2237005A1 (en)	1997-06-26
GB9624482D0 (en)	1997-01-15
NO311358B1 (no)	2001-11-19
SK282443B6 (sk)	2002-02-05
EP0873319B1 (en)	2001-07-25
NZ324007A (en)	1999-11-29
MX9804247A (es)	1998-09-30

Publication	Publication Date	Title
PL327310A1 (en)	1998-12-07	Derivatives of quinazoline
IL128994A0 (en)	2000-02-17	Quinoline derivatives inhibiting the effect of growth factors such as vegf
CA2344290A1 (en)	2000-04-20	Quinazoline derivatives
CA2263319A1 (en)	1998-04-02	Quinazoline derivatives and pharmaceutical compositions containing them
PL328310A1 (en)	1999-01-18	Derivatives of quinazoline
UA72946C2 (uk)	2005-05-16	Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
IL111959A (en)	2000-07-16	N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
EP0654032A1 (en)	1995-05-24	Quinuclidine derivatives as squalene synthase inhibitors.
ATE215075T1 (de)	2002-04-15	Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend